secwatch.observer — SEC 8-K summary
======================================

Issuer:     Transcode Therapeutics, Inc. (RNAZ)
CIK:        0001829635
Form:       8-K
Filed at:   2023-12-04T23:59:59+00:00
Accession:  0001104659-23-123274
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 1.01, 3.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

TransCode Therapeutics raises $1.21M in registered direct offering of 5M shares at $0.242/share
--------------------------------------------------------------------------------

- Sold 5,000,000 shares of common stock at $0.242 per share, gross proceeds of $1.21 million.
- Offering closed on December 4, 2023; H.C. Wainwright & Co. acted as exclusive placement agent.
- Placement agent received warrants to purchase 300,000 shares at $0.3025 per share, exercisable for 5 years.
- Net proceeds will fund clinical trials for lead candidate TTX-MC138 and for working capital.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1829635/000110465923123274/0001104659-23-123274-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1829635/000110465923123274/tm2332042d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-123274

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer